小分子化合物抗丙型肝炎治疗新方案

摘要

A relatively complete hepatitis C guideline updated by the American Society for Study of Liver Diseases and the In-fectious Diseases Society of America was published in Hepatology on June 30, 2015. In this guideline, consensus on recommendations for treating adults infected with HCV is reached. The choice of direct-acting antiviral agents (DAAs) may involve the consideration of HCV genotype, prior treatment response, DAA-resistance mutations, etc., so as to optimize treatment options and improve antiviral effi-cacy. Meanwhile, standardizing the rational use of DAAs in clinical practice may prevent drug resistance and reduce cost of treatment.%2015年6月30日Hepatology发布由美国肝病研究学会和美国感染病学会更新的相对完善的丙型肝炎诊治指南推荐意见，就成人丙型肝炎患者的治疗方案达成共识。直接抗病毒药物（direct-acting antiviral agents, DAAs）的类型选择基于HCV基因分型、既往治疗应答情况以及是否存在DAAs相关耐药位点等问题的综合考虑，以便优化治疗，提高抗病毒疗效。同时规范临床合理使用DAAs，可以防止耐药发生，降低治疗成本。